The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver metastasis.
Jun Ho Ji
No relevant relationships to disclose
Young Suk Park
No relevant relationships to disclose
Jeeyun Lee
No relevant relationships to disclose
Tae Won Kim
No relevant relationships to disclose
Yong Sang Hong
No relevant relationships to disclose
Kyu-Pyo Kim
No relevant relationships to disclose
Sun Young Kim
No relevant relationships to disclose
Ji Yeon Baek
No relevant relationships to disclose
Hye Jin Kang
No relevant relationships to disclose
Sang Joon Shin
No relevant relationships to disclose
Byoung Yong Shim
No relevant relationships to disclose